CLINICAL EXPERIENCE WITH DOLUTEGRAVIR IN A TERTIARY HOSPITAL
DI-019
EFFECT AND SAFETY OF MEXILETINE ON SIGNS AND SYMPTOMS OF MYOTONIC DISORDERS
DI-017
MEFLOQUINE IN PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
DI-016
PREVENTION OF TOXOPLASMIC ENCEPHALITIS AND PNEUMOCYSTIS JIROVECI PNEUMONIA IN PATIENTS INFECTED WITH HIV: EFFICACY AND SAFETY OF DAPSONE/PYRIMETHAMINE/LEUCOVORIN
DI-015
USE OF OMALIZUMAB FOR TREATMENT OF MAST CELL ACTIVATION DISEASE
DI-014
EFFICACY AND SAFETY OF FINGOLIMOD IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS
DI-013
USE OF TUBERCULOSTATIC IN PREGNANCY WITH FATAL RESULTS: A CASE REPORT
DI-012
SAFETY PROFILE OF JANUS ASSOCIATED KINASE INHIBITORS
DI-010
BLEOMYCIN SCLEROTHERAPY IN VASCULAR MALFORMATIONS
DI-009
CLINICAL AND ECONOMIC ASSESSMENT AFTER CHANGING BASILIXIMAB PROTOCOL IN HEPATIC TRANSPLANTATION
DI-008
APPS FOR PAEDIATRIC DOSING – AN EVALUATION
DI-007
EFFECTIVENESS AND SECURITY OF SUSTAINED RELEASE FAMPRIDINE IN MULTIPLE SCLEROSIS IN THE SHORT TERM
DI-005
CANNABINOID USE IN THERAPY: FIRST MONITORING OF ADVERSE REACTIONS
DI-003
PACLITAXEL-CARBOPLATIN INDUCED PERIPHERAL NEUROPATHY IN OVARIAN CANCER PATIENTS
DI-077
USE OF ROMIPLOSTIM IN PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA
